These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1508379)

  • 1. [Effectiveness of transdermal administration of 17-beta-estradiol in the management of menopause].
    Grio R; Piacentino R; Abbondanza M; Cirnigliaro C; Fusi D; Corsello FP; Arrichiello G; Canestrelli M; Marchino GL
    Minerva Ginecol; 1992; 44(1-2):19-21. PubMed ID: 1508379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Transdermal estrogenic therapy in menopause].
    Nencioni T; Polvani F; Penotti M; Porcaro E; Barbieri Carones M
    Minerva Endocrinol; 1989; 14(1):49-52. PubMed ID: 2543896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
    Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sexually and well-being in early menopause. Effect of transdermal estradiol therapy.
    Rigano A; Rigano M; Cancellieri F; Pullè C
    Panminerva Med; 2001 Jun; 43(2):115-8. PubMed ID: 11449182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal symptoms and lipid metabolism].
    Giuliani A; Concin H; Wieser F; Boritsch J; Wilfert H; Gruber D; Urdl W
    Wien Klin Wochenschr; 2000 Jul; 112(14):629-33. PubMed ID: 11008325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transdermal estrogen substitution in the postmenopause].
    Fontana-Klaiber H; Koller J; Keller PJ
    Gynakol Rundsch; 1987; 27(4):225-33. PubMed ID: 3436573
    [No Abstract]   [Full Text] [Related]  

  • 7. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal estrogen.
    Med Lett Drugs Ther; 1986 Dec; 28(728):119-20. PubMed ID: 3784967
    [No Abstract]   [Full Text] [Related]  

  • 9. Estrasorb.
    Chiechi LM
    IDrugs; 2004 Sep; 7(9):860-4. PubMed ID: 15470604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women.
    Naunton M; Al Hadithy AF; Brouwers JR; Archer DF
    Menopause; 2006; 13(3):517-27. PubMed ID: 16735950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Systemic sensitization to 17-beta estradiol induced by transcutaneous administration].
    El Sayed F; Bayle-Lebey P; Marguery MC; Bazex J
    Ann Dermatol Venereol; 1996; 123(1):26-8. PubMed ID: 8734113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulsed estrogen therapy: from cellular mode of action to tissue effects.
    Al-Azzawi F
    Climacteric; 2002 Jun; 5 Suppl 2():27-31. PubMed ID: 12482108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
    Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
    Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two routes of hormonal replacement therapy in symptomatic menopausal women after kidney transplantation.
    Pietrzak B; Wielgos M; Kaminski P; Bobrowska K
    Neuro Endocrinol Lett; 2006 Jun; 27(3):387-91. PubMed ID: 16816826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Transcutaneous estradiol treatment in the climacteric].
    Pedersen OD; Jensen HK
    Ugeskr Laeger; 1990 Sep; 152(36):2561-4. PubMed ID: 2402844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal estradiol: new formulation. Intranasal oestrogen delivery system: just a gimmick.
    Prescrire Int; 2002 Dec; 11(62):163-5. PubMed ID: 12469692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systen--transdermal estradiol for substitution following surgical menopause].
    Rachev E; Karag'ozov I
    Akush Ginekol (Sofiia); 1995; 34(3):74-6. PubMed ID: 8743861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial.
    Baksu B; Baksu A; Göker N; Citak S
    Maturitas; 2009 Feb; 62(2):140-5. PubMed ID: 19179026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
    Shulman LP
    J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108
    [No Abstract]   [Full Text] [Related]  

  • 20. [Urinary estrogens after administration of estradiol benzoate in menopausal women].
    Subrizi DA; Curiel P; Gentile G
    Riv Ostet Ginecol; 1967 Jul; 22(7):484-92. PubMed ID: 5612909
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.